Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. Van Der Velden, H. Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Elena Zamagni, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2023-178533

Published: 2023

Journal Articles

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Blood (2023) 142 (Supplement 1): 208.

https://doi.org/10.1182/blood-2023-177564

Published: 2023

Journal Articles

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 4.

https://doi.org/10.1182/blood-2023-177546

Published: 2023

Journal Articles

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. van der Velden, Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 10177–10179.

https://doi.org/10.1182/blood-2022-160004

Published: 2022

Journal Articles

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Blood (2022) 140 (Supplement 1): 1566–1567.

https://doi.org/10.1182/blood-2022-170249

Published: 2022

Journal Articles

Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma

Madelon M.E. de Jong, Cathelijne Fokkema, Natalie Papazian, Teddie van Heusden, Michael Vermeulen, Sabrin Tahri, Remco Hoogenboezem, Mark van Duin, Pieter van de Woestijne, Anton Langerak, Annemiek Broijl, Pieter Sonneveld, Tom Cupedo

Blood (2022) 140 (Supplement 1): 4181–4182.

https://doi.org/10.1182/blood-2022-166339

Published: 2022

Journal Articles

MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course

Cathelijne Fokkema, Madelon M.E. de Jong, Sabrin Tahri, Davine Hofste Op Bruinink, Zoltan Kellermayer, Chelsea den Hollander, Michael Vermeulen, Natalie Papazian, Mark van Duin, Remco Hoogenboezem, Michiel J.W. Wevers, Vincent H.J. van der Velden, Mathijs A. Sanders, Annemiek Broijl, Pieter Sonneveld, Tom Cupedo

Blood (2022) 140 (Supplement 1): 9917–9918.

https://doi.org/10.1182/blood-2022-166162

Published: 2022

Journal Articles

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Sabrin Tahri, Madelon M.E. de Jong, Cathelijne Fokkema, Natalie Papazian, Zoltan Kellermayer, Michael Vermeulen, Mark van Duin, Pieter van de Woestijne, Kazem Nasserinejad, Elona Saraci, Mattia D'Agostino, Francesca Gay, Vincent H.J. van der Velden, Niels WCJ Van De Donk, Annemiek Broijl, Pieter Sonneveld, Sonja Zweegman, Tom Cupedo

Blood (2022) 140 (Supplement 1): 9982–9984.

https://doi.org/10.1182/blood-2022-164812

Published: 2022

Journal Articles

Inflammasome-Primed Myeloid Cells Maintain a Pro-Tumor Microenvironment in Multiple Myeloma

Madelon M.E. de Jong, Cathelijne Fokkema, Natalie Papazian, Sabrin Tahri, Zoltan Kellermayer, Michael Vermeulen, Mark van Duin, Pieter van de Woestijne, Annemiek Broyl, Pieter Sonneveld, Tom Cupedo

Blood (2021) 138 (Supplement 1): 2679.

https://doi.org/10.1182/blood-2021-150327

Published: 2021

Journal Articles

Single-Cell Transcriptomic Analysis Reveals Loss of Activated Bone Marrow NK Cells in Multiple Myeloma Patients Which Associates with Disease Progression in Mice

Sabrin Tahri, Zoltan Kellermayer, Madelon M.E. de Jong, Natalie Papazian, Cathelijne Fokkema, Chelsea den Hollander, Pieter van de Woestijne, Mark van Duin, Annemiek Broijl, Pieter Sonneveld, Tom Cupedo

Blood (2021) 138 (Supplement 1): 1578.

https://doi.org/10.1182/blood-2021-150422

Published: 2021

Journal Articles

High Levels of Circulating Tumor Cells Are Associated with Increased Bone Marrow Proliferation in Newly Diagnosed Multiple Myeloma Patients

Cathelijne Fokkema, Madelon M.E. de Jong, Sabrin Tahri, Zoltan Kellermayer, Chelsea den Hollander, Michael Vermeulen, Natalie Papazian, Mark van Duin, Michiel J.W. Wevers, Mathijs A. Sanders, Vincent H.J. van der Velden, Pieter Sonneveld, Annemiek Broyl, Tom Cupedo

Blood (2021) 138 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2021-145971

Published: 2021

Journal Articles

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Rowan Kuiper, PhD, Mark van Duin, PhD, Martin H Van Vliet, Erik H Van Beers, PhD, Berna Berna Beverloo, PhD, Sonja Zweegman, MD PhD, Tom Cupedo, PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139987

Published: 2020

Journal Articles

Peripheral Neuropathy in the Cassiopeia Study

Cathelijne Fokkema, MD, Bronno Van Der Holt, PhD, Mark van Duin, PhD, Ruth Wester, MD, Tom Cupedo, PhD, Philippe Moreau, MD, Jessica Vermeulen, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-137400

Published: 2020

Journal Articles

Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials

Mark van Duin, Annemiek Broijl, Jasper Koenders, Sonja Zweegman, Monique C. Minnema, Francois G. Kavelaars, Remco Hoogenboezem, Kazem Nasserinejad, Mario Boccadoro, Peter Valk, PhD, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 1798.

https://doi.org/10.1182/blood-2019-130086

Published: 2019

Journal Articles

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Pim Mutsaers, MD, Rowan Kuiper, MSc, Dora Hammerl, Msc, Mark van Duin, PhD, Bronno Van Der Holt, PhD, Sonja Zweegman, MDPhD, Walter M Gregory, Jan J Cornelissen, MD PhD, Annemiek Broyl, MD PhD, Reno Debets, PhD, Pieter Sonneveld, MDPhD

Blood (2018) 132 (Supplement 1): 241.

https://doi.org/10.1182/blood-2018-99-118488

Published: 2018

Journal Articles

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Davine Hofste op Bruinink, MD MSc, Mark van Duin, PhD, Meral Beksac, MD, Christoph Driessen, MD, Heinz Ludwig, MD, Michael Vermeulen, BSc, Rowan Kuiper, MSc, Martin H van Vliet, PhD, Bronno van der Holt, PhD, Roman Hajek, MD PhD, Hans Erik Johnsen, MD Professor, Meletios A Dimopoulos, MD, Antonio Palumbo, MD, Michele Cavo, MD, Pieter Sonneveld, MD PhD

Blood (2018) 132 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2018-99-119873

Published: 2018

Journal Articles

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Davine Hofste Op Bruinink, MD, Vincent van der Velden, PhD, Mark van Duin, PhD, Berna Beverloo, PhD, Jeroen te Marvelde, BSc, Chelsea den Hollander, BSc, Rowan Kuiper, MSc, Michel Delforge, MDPhD, Martin H van Vliet, PhD, Niels WCJ van de Donk, MDPhD, Hervé Avet-Loiseau, MDPhD, Philippe Moreau, MDPhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 4368.

https://doi.org/10.1182/blood.V130.Suppl_1.4368.4368

Published: 2017

Journal Articles

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS

Ruth Wester, King Hong Lam, MD PhD, Mark van Duin, PhD, Suzana Couto, Yan Ren, Maria Wang, PhD, Bronno van der Holt, Berna Beverloo, PhD, Heleen Visser-Wisselaar, Alex Nigg, Max Qian, Anjan Thakurta, PhD, Annemiek Broyl, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3052.

https://doi.org/10.1182/blood.V130.Suppl_1.3052.3052

Published: 2017

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy E. Axel, Khaja Syed, Richard W. J. Groen, Mark van Duin, Pieter Sonneveld, Monique C. Minnema, Sonja Zweegman, Christopher Chiu, Andries C. Bloem, Tuna Mutis, Henk M. Lokhorst, A. Kate Sasser, Niels W. C. J. van de Donk

Blood (2016) 128 (7): 959–970.

https://doi.org/10.1182/blood-2016-03-703439

Published: 2016

Includes: Supplemental data

NARROW

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma

MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Inflammasome-Primed Myeloid Cells Maintain a Pro-Tumor Microenvironment in Multiple Myeloma

Single-Cell Transcriptomic Analysis Reveals Loss of Activated Bone Marrow NK Cells in Multiple Myeloma Patients Which Associates with Disease Progression in Mice

High Levels of Circulating Tumor Cells Are Associated with Increased Bone Marrow Proliferation in Newly Diagnosed Multiple Myeloma Patients

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Peripheral Neuropathy in the Cassiopeia Study

Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only